News Notification

The Brigham and Dana-Farber Board Review in Hematology and Oncology

327 views Tags: CME Brigham Board Review

The Brigham and Dana-Farber Board Review in Hematology and Oncology

Brigham and Women’s Hospital Board Review

This comprehensive CME program offers an in-depth, case-base review of the clinical essentials in hematology and oncology.

Improve Patient Care in Hematology and Oncology

The Brigham and Dana-Farber Board Review in Hematology and Oncology will help improve clinical practice gaps in hematology and oncology derived from the American Board of Internal Medicine (ABIM) certification/recertification requirements. Relevant topics are addressed in case-based board review presentations. Improve patient care by learning to:

– Perform differential diagnosis of complex hematologic and oncologic disorders

– Identify and apply current therapeutic options for hematologic and oncologic disorders

– Evaluate and interpret up-to-date literature relevant to hematology and oncology

– Illustrate knowledge of pathophysiology of hematologic and oncologic disorders

– Illustrate knowledge of pathophysiology as it applies to management of Hematology and Oncology disorders

– Apply knowledge gained to the ABIM certification/recertification Hematology and Oncology examinations

CHECK SAMPLES

Board Review in Hematology and Oncology Topics

1

Molecular Genetics of Cancer – Nikhil Wagle, MD

2

Advances in Cancer Drug Development – Geoffrey I. Shapiro, MD, PhD

3

Infections in Cancer Patients – Lindsey Baden, MD

4

Symptom Management in Patients with Cancer – Janet L. Abrahm, MD

5

Communication: The Key to Excellence in End-of-Life Care – Susan D. Block, MD

6

Biology of Hematopoietic Stem Cell Transplantation – Robert J. Soiffer, MD

7

Biology of Acute Leukemia and Myelodysplastic Syndromes – Benjamin L. Ebert, MD, PhD

8

Acute Leukemias – Daniel J. DeAngelo, MD, PhD

9

Myelodysplastic Syndrome – David P. Steensma, MD

10

Chronic Myelogenous Leukemia – Joseph H. Antin, MD

11

Myeloproliferative Syndromes – Ann M. Mullally, MD

12

Multiple Myeloma – Kenneth C. Anderson, MD

13

Waldenstrom Macroglobulinemia, Amyloidosis – Irene M. Ghobrial, MD

14

Low Grade Lymphomas – Caron A. Jacobson, MD

15

High Grade Lymphomas – Eric D. Jacobsen, MD

16

Hodgkin’s Lymphoma – Ann S. LaCasce, MD

17

Diagnosis and Treatment of CLL and Related B Cell Malignancies – Matthew S. Davids, MD

18

Head and Neck Cancer – Robert I. Haddad, MD

19

Natural History, Screening, Surgery, Small Cell Lung Cancer – Bruce E. Johnson, MD

20

Non Small Cell Lung Cancer – Mark Awad, MD, PhD

21

Mesothelioma and Thymoma – David M. Jackman, MD

22

Thyroid Cancer – Jochen Lorch, MD

23

Carcinoid and Pancreatic Neuroendocrine Tumors – Jennifer Ang Chan, MD

24

Esophageal and Gastric Cancer – Peter C. Enzinger, MD

25

Pancreatic and Hepatobiliary Cancer – Brian M. Wolpin, MD

26

Anal Cancers – Robert J. Mayer, MD

27

Colorectal Cancers – Robert J. Mayer, MD

28

Gastrointestinal Cancer – Genetic Syndromes – Matthew Yurgelun, MD

29

Gastrointestinal Cancer – Genetic Syndromes – Matthew Yurgelun, MD

30

Renal and Bladder Cancer – Toni K. Choueiri, MD

31

Prostate Cancer Part I: Overview and Management of Localized Disease – Atish Choudhury, MD, PhD

32

Prostate Cancer Part II: Management of Disseminated Prostate Cancer – Atish Choudhury, MD, PhD

33

Melanoma – F. Stephen Hodi, MD

34

Sarcomas and Gastrointestinal Stromal Tumors (GIST) – George D. Demetri, MD

35

Ovarian Cancer – Ursula A. Matulonis, MD

36

Cervical and Endometrial Cancer – Panagiotis A. Konstantinopoulos, MD, PhD

37

Neuro-oncology – David A. Reardon, MD

38

Breast Cancer: Risk Factors, Genetics, Screening and Prevention – Judy E. Garber, MD, MPH

39

Breast Cancer: Advances in Staging, Prognosis, Surgery and Radiation, and DCIS – Harold J. Burstein, MD, PhD

40

Management for HER2-Positive and Triple Negative Breast Cancer – Eric P. Winer, MD

41

Breast Cancer Survivorship – Ann H. Partridge, MD, MPH

42

Hematopoiesis and Cytokines – David T. Scadden, MD

43

Acquired Bone Marrow Failure – Julie-Aurore Losman, MD, PhD

44

Congenital Bone Marrow Failure – David A. Williams, MD

45

Hemophagocytic Syndromes and Related Immunodeficiencies – Barbara A. Degar, MD

46

Anemia: An Overview – Ronald P. McCaffrey, MD

47

Iron Deficiency and Iron Overload – Mark D. Fleming, MD, PhD

48

Immune Hemolytic Anemia – Richard M. Kaufman, MD

49

Non-immune Hemolytic Anemia – David E. Golan, PhD, MD

50

Sickle Cell Disease – Maureen M. Achebe, MD, MPH

51

Thalassemia and Other Hemoglobinopathies – Matthew M. Heeney, MD

52

Disorders of Neutrophils – Nancy Berliner, MD

53

Acquired Thrombocytopenias – Elisabeth M. Battinelli, MD, PhD

54

Hemophilia – Aric D. Parnes, MD

55

Von Willebrand Disease and Congenital Platelet Disorders – Nathan T. Connell, MD, MPH

56

Congenital and Acquired Thrombophilia – Kenneth A. Bauer, MD

57

New Oral Anticoagulants – Jean M. Connors, MD

58

Transfusion Medicine for the Clinician – Walter H. Dzik, MD

Learning Objectives

After viewing this program, participants should be able to:

– Apply current/recommended Hematology and Oncology guidelines in clinical practice

– Perform differential diagnosis of complex clinical presentations related to Hematologic and Oncologic disorders

– Identify/apply current therapeutic options for for specific Hematologic and Oncologic disorders

– Evaluate and interpret up-to-date literature relevant to clinical practice in Hematology and Oncology

– Illustrate knowledge of pathophysiology as it applies to management of Hematology and Oncology disorders

– Apply knowledge gained to the ABIM certification/recertification Hematology and Oncology examinations

Intended Audience

The activity was planned for fellows/trainees, practicing Hematology and Oncology specialists (MDs), and other professional affiliates (internists with an interest in Hematology and Oncology) who are preparing to take ABIM Board Review or Recertification Examinations, or who seek CME activities to improve patient care in the areas of Hematology and Oncology Medicine.

Designation

Date of Original Release: June 30, 2018

Date Credits Expire: June 30, 2021

Leave a Reply

avatar
error: Content is protected !!